GlassScriptPhysician profile
Samer H Jaber
NPI 1942343769
$19,856.56
in general payments reported to CMS, 2019-2025
43 companies · $2,927 in 2025
The $2,927 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,706 · 2020: $1,651 · 2021: $2,651 · 2022: $3,429 · 2023: $2,575 · 2024: $2,919 · 2025: $2,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,339 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,339.47 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,034.95 | 2019-2025 | |
| Epi Health, LLC | $1,899.12 | 2019-2022 | |
| Galderma Laboratories, L.P. | $1,689.54 | 2019-2025 | Aklief, Twyneo, Epsolay |
| Regeneron Healthcare Solutions, INC. | $1,475.42 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $1,338.76 | 2019-2025 | Tremfya, Erleada |
| Sun Pharmaceutical Industries INC. | $1,059.17 | 2019-2025 | Absorica Ld, Winlevi |
| Genzyme Corporation | $926.10 | 2019-2025 | |
| Leo Pharma INC. | $743.49 | 2019-2025 | Adbry, Anzupgo |
| Merz North America, INC. | $742.30 | 2019-2022 | |
| Pfizer INC. | $739.53 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $737.24 | 2019-2025 | |
| Incyte Corporation | $718.25 | 2021-2025 | Opzelura |
| Allergan, INC. | $678.27 | 2019-2022 | |
| Dermavant Sciences, INC. | $553.74 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $549.65 | 2019-2025 | Cabtreo, Jublia, Arazlo |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $379.01 | 2019-2023 | Klisyri, Seysara |
| Mayne Pharma Commercial LLC | $361.80 | 2019-2023 | |
| Arcutis Biotherapeutics, INC. | $323.83 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $309.74 | 2019-2025 | Taltz, Ebglyss |
| Vyne Pharmaceuticals INC. | $248.42 | 2020-2021 | |
| Amgen INC. | $224.14 | 2019-2025 | Otezla, Otezla |
| Organon LLC | $188.62 | 2025 | Vtama |
| Celgene Corporation | $119.94 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $94.81 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $94.76 | 2022-2024 | Sotyktu |
| Dermira, INC. | $93.98 | 2019-2020 | |
| Journey Medical Corporation | $80.27 | 2020-2025 | |
| Ucb, INC. | $77.87 | 2023-2024 | Bimzelx, Cimzia |
| Aclaris Therapeutics, INC. | $65.22 | 2019 | |
| Urogen Pharma, INC. | $45.61 | 2025 | |
| Mission Pharmacal Company | $28.45 | 2019-2021 | |
| Sanofi Pasteur INC. | $27.39 | 2024 | |
| Dusa Pharmaceuticals, INC. | $24.79 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.87 | 2020 | |
| Verrica Pharmaceuticals INC. | $21.95 | 2023 | Ycanth |
| Prugen, INC. Pharmaceuticals | $21.65 | 2019 | |
| Mylan Pharmaceuticals INC. | $20.01 | 2019 | |
| Lnhc, INC | $19.06 | 2025 | Zelsuvmi |
| Teleflex LLC | $16.55 | 2025 | Urolift |
| Sumitomo Pharma America, INC. | $16.00 | 2025 | Gemtesa |
| Acelrx Pharmaceuticals, INC. | $15.46 | 2022 | |
| Botanix Sb INC | $14.97 | 2025 | Sofdra |
| Promius Pharma LLC | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Jaber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.